National Biotechnology Centre (CNB-CSIC)
If you are the contact person for this centre and you wish to make any changes, please contact us.
Co-director of the Microbiome Analysis Laboratory and Research Professor
Co-director of the coronavirus group at the National Biotechnology Centre (CNB-CSIC)
Research professor at the National Biotechnology Centre (CNB-CSIC) and at the CIBERER-ISCIII
CNB-CSIC Scientific Researcher at the CiMUS of the University of Santiago de Compostela, IDIS. Laboratory of Cell Senescence, Cancer and Aging
Virologist at the National Center for Biotechnology (CNB-CSIC)
Researcher at the National Biotechnology Centre (CNB-CSIC)
Researcher specialized in ecology and evolution of antibiotic resistance.
Virologist at the National Biotechnology Centre (CNB-CSIC)
CSIC Research Professor at the National Center of Biotechnology
A review with meta-analysis published in the journal PLoS Medicine concludes that the percentage of asymptomatic people with covid-19 is lower, and that they are less contagious than those who are pre-symptomatic or symptomatic.
On 18 May, the Ministry of Health confirmed to SMC Spain that eight suspected cases "clinically compatible" with monkeypox had been detected. The same afternoon, the Consejería de Sanidad de la Comunidad de Madrid reported that it had detected 23 possible cases of infection. These cases need to be confirmed after testing. At least 7 cases have been confirmed in the UK and Portugal. This is a rare zoonotic viral disease and there is no vaccine or specific treatment available. Treatment is symptomatic and supportive. Most cases are resolved favourably.
The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) consider it too early for the general population to receive a fourth dose of covid-19 mRNA vaccines. Both agencies do agree that people over 80 years of age should receive it because of their increased risk of severe disease.
Two studies published in The Lancet Infectious Diseases confirm that covid-19 vaccines offer additional protection for those already infected with SARS-CoV-2, especially against severe disease.
La EMA ha recomendado hoy la autorización de la quinta vacuna frente a la covid-19 para mayores de 18 años: la estadounidense Novavax, la primera basada en una plataforma de proteínas recombinantes.
The new B.1.1.529 variant, dubbed Omicron, has spread across the globe, with new countries announcing its detection with each passing day. While questions such as whether it is more transmissible are being investigated, the biggest question surrounds its relationship with vaccines - will they cease to be effective, and will this variant escape our immune systems? Several experts answer.